Robbins Gregory K, Daniels Brock, Zheng Hui, Chueh Henry, Meigs James B, Freedberg Kenneth A
Division of Infectious Diseases, Massachusetts General Hospital, Harvard Center for AIDS Research (CFAR), and Harvard Medical School, Boston, MA 02114, USA.
J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):30-7. doi: 10.1097/01.qai.0000248351.10383.b7.
Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations.
A retrospective analysis was conducted of HIV-infected patients followed in an urban HIV clinic with an HIV RNA measurement < or =400 copies/mL on ART between January 1, 2003, and December 31, 2004. The primary endpoint was treatment failure, defined as virologic failure (> or =1 HIV RNA measurement >400 copies/mL), unsanctioned stopping of ART, or loss to follow-up. Prior ART adherence and other baseline patient characteristics, determined at the time of the first suppressed HIV RNA load on or after January 1, 2003, were extracted from the electronic health record (EHR). Predictors of failure were assessed using proportional hazards modeling.
Of 829 patients in the clinic, 614 had at least 1 HIV RNA measurement < or =400 copies/mL during the study period. Of these, 167 (27.2%) experienced treatment failure. Baseline characteristics associated with treatment failure in the multivariate model were: poor adherence (hazard ratio [HR] = 3.44; 95% confidence interval [CI]: 2.34 to 5.05), absolute neutrophil count <1000/mm (HR = 2.90, 95% CI: 1.26 to 6.69), not suppressed on January 1, 2003 (HR = 2.69, 95% CI: 1.78 to 4.07) or <12 months of suppression (HR = 1.64, 95% CI: 1.10 to 2.45), CD4 count <200 cells/mm (HR = 1.90, 95% CI: 1.31 to 2.76), nucleoside-only regimen (HR = 1.75, 95% CI: 1.08 to 2.82), prior virologic failure (HR = 1.70, 95% CI: 1.22 to 2.39) and > or =1 missed visit in the prior year (HR = 1.56, 95% CI: 1.13 to 2.16).
More than one quarter of patients in a heterogeneous clinic population had treatment failure over a 2-year period. Prior ART adherence and other EHR data readily identify patient characteristics that could trigger specific interventions to improve ART outcomes.
抗逆转录病毒治疗(ART)失败的预测因素在异质性临床人群中尚未得到充分表征。
对2003年1月1日至2004年12月31日期间在一家城市HIV诊所接受ART治疗且HIV RNA测量值≤400拷贝/mL的HIV感染患者进行回顾性分析。主要终点是治疗失败,定义为病毒学失败(≥1次HIV RNA测量值>400拷贝/mL)、未经批准停止ART或失访。从电子健康记录(EHR)中提取2003年1月1日或之后首次出现HIV RNA负荷被抑制时的既往ART依从性及其他基线患者特征。使用比例风险模型评估失败的预测因素。
诊所的829名患者中,614名在研究期间至少有1次HIV RNA测量值≤400拷贝/mL。其中,167名(27.2%)经历了治疗失败。多变量模型中与治疗失败相关的基线特征为:依从性差(风险比[HR]=3.44;95%置信区间[CI]:2.34至5.05)、绝对中性粒细胞计数<1000/mm³(HR=2.90,95%CI:1.26至6.69)、2003年1月1日未被抑制(HR=2.69,95%CI:1.78至4.07)或抑制时间<12个月(HR=1.64,95%CI:1.10至2.45)、CD4细胞计数<200个/mm³(HR=1.90,95%CI:1.31至2.76)、仅使用核苷类药物方案(HR=1.75,95%CI:1.08至2.82)、既往病毒学失败(HR=1.70,95%CI:1.22至2.39)以及上一年度≥1次漏访(HR=1.56,95%CI:1.13至2.16)。
在一个异质性临床人群中,超过四分之一的患者在2年期间出现治疗失败。既往ART依从性及其他EHR数据能够轻易识别出可能触发特定干预措施以改善ART结局的患者特征。